Swipe om te navigeren naar een ander artikel
Systemic corticosteroids (SCS) are commonly used but are associated with adverse effects. Given their prevalent use, the potential impact of SCS use on health-related quality of life (HRQoL) is important to characterize.
To assess the HRQoL of patients taking SCS.
The 2000–2003 Medical Expenditure Panel Survey was used to examine EQ-5D and SF-6D scores associated with SCS use in adults. The study sample was restricted to those with a condition for which SCS are prescribed. SCS use was categorized into three levels: none; 1–3; and ≥4 prescriptions per year. HRQoL scores were regressed on SCS use (1–3 or ≥4 annual prescriptions) controlling for age, gender, race, ethnicity, education, income category, geographic region, number of ER visits, number of outpatient visits, total number of chronic conditions (for which SCS are not used) and conditions for which SCS are clinically indicated.
There were 54,856 individuals with no SCS exposure, 2245 with 1–3 and 624 with ≥4 annual SCS prescriptions. In adjusted analyses, use of ≥4 annual SCS prescriptions appeared to be associated with significantly lower EQ-5D (US), EQ-5D (UK), SF-6D and EQ-5D VAS scores compared to no exposure: −0.032, −0.047, −0.036, and −7.58.
While SCS are efficacious and widely used for numerous conditions, results suggest that their use may be associated with a substantial deleterious impact on HRQoL. This potential negative effect should be considered in balance with the cost and efficacy of comparable treatments.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Global Initiative for Asthma (GINA) NH, Lung, and Blood Institute (NHLBI). Global strategy for asthma management and prevention. Bethesda, MD2012.
Weiss, A., Elixhauser, A., Bae, J., & Encinosa, W. (2013). Origin of adverse drug events in US Hospitals, 2011. Statistical Brief #158. Rockville, MD: Healthcare Cost and Utilization Project (HCUP).
Agency for Healthcare Research and Quality (AHRQ). MEPS HC-079: 2003 Full Year Consolidated Data File. 2003; http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h79/h79doc.pdf. Accessed 14 Oct 2012.
The EuroQol Group. EQ-5D Reference Search. (2016). http://www.euroqol.org/eq-5d-publications/search.html. Accessed 10 May 2013.
Powell, J. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25, 303–325. CrossRef
Maddala, G. S. (1999). Limited-dependent and qualitative variables in econometrics. Cambridge: Cambridge University Press.
Green, W. H. (2000). Econometric analysis (4th ed.). Upper Saddle River, NJ: Prentice Hall.
Brown, E. S., & Chandler, P. A. (2001). Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion Journal of Clinical Psychiatry, 3(1), 17–21. CrossRef
Basch, E., Reeve, B. B., Mitchell, S. A., et al. (2014). Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute. doi: 10.1093/jnci/dju244.
- Health-related quality of life associated with systemic corticosteroids
Patrick W. Sullivan
Vahram H. Ghushchyan
- Springer International Publishing